丁苯酞联合依达拉奉治疗急性脑梗死的效果分析

Curative effect analysis on Butylphthalide combined with Edaravone treating acute cerebral infarction patients

目的探讨丁苯酞联合依达拉奉治疗急性脑梗死的临床效果。方法将80例急性脑梗死患者随机分为对照组和联合组，各40例，对照组给予依达拉奉等常规治疗，而联合组则在此基础上加服丁苯酞软胶囊治疗；比较两组患者的炎性指标、NIHSS评分、Barthel评分、总有效率及不良反应。结果治疗30天后，联合组的CRP、IL-4水平均明显低于对照组（P〈0．01）；联合组的NIHSS评分、Barthel评分均明显高于对照组（P〈0．01）；联合组的总有效率为95．6％，明显高于对照组的80．O％（P〈0．05）；两组患者治疗过程中的不良反应发生率比较无统计学差异（P〉0．05）。结论丁苯酞联合依达拉奉治疗急性脑梗死患者，可降低炎症反应，改善神经功能和日常生活活动能力评分，提高治疗总有效率，不良反应率低，值得在临床推广应用。’

Objective To explore clinical curative effect of Butylphthalide combined with Edaravone treating acute cere- bral infarction patients. Methods Eighty patients with acute cerebral infarction were randomly divided into control group （40 cases） and combination group （40 cases）. The control group was given Edaravone and conventional treatment, while the combi- nation group was given Butylphthalide soft capsule on the basis of the control group. The indexes of inflammatory reaction, NIHSS score, Barthel score, total effective rate and adverse effect were compared between the groups. Results After 30 days treat- ment, the levels of CRP and IL-4 in the combination group were much lower than those in the control group （P〈0.01）. NIHSS score and Barthel score in the combination group were much higher than those in the control group （P〈0.01）. The total effective rate in the combination group was 95.6%, much higher than that in the control group （80.0%, P〈0.05）. There was no statis- tical significance about adverse effect rate between the two groups. Conclusion Treating acute cerebral infarction patients with Butylphthalide combined with Edaravone could cut down inflammatory reaction, improve nerve function and activities of daily liv- ing, raise total effective rate, and lower adverse effect. So it deserves to spread in clinic.